mesalamine has been researched along with Flatulence in 2 studies
Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.
Flatulence: Production or presence of gas in the gastrointestinal tract which may be expelled through the anus.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients who received mesalamine plus the mixture of beta-glucan, inositol and digestive enzymes (group A) reported a reduction in abdominal pain together with reduction in bloating and flatulence after four weeks of treatment." | 9.24 | Beta-glucan, inositol and digestive enzymes improve quality of life of patients with inflammatory bowel disease and irritable bowel syndrome. ( Cosco, C; Cosco, V; Doldo, P; Garieri, P; Mancina, RM; Ruggiero, G; Spagnuolo, R, 2017) |
| "Patients who received mesalamine plus the mixture of beta-glucan, inositol and digestive enzymes (group A) reported a reduction in abdominal pain together with reduction in bloating and flatulence after four weeks of treatment." | 5.24 | Beta-glucan, inositol and digestive enzymes improve quality of life of patients with inflammatory bowel disease and irritable bowel syndrome. ( Cosco, C; Cosco, V; Doldo, P; Garieri, P; Mancina, RM; Ruggiero, G; Spagnuolo, R, 2017) |
| " Given the high use of complementary alternative medicines in pediatric IBD, a prospective tolerability study of curcumin, an herbal therapy with known anti-inflammatory effects, was conducted to assess possible dosage in children with IBD." | 2.78 | Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study. ( Burpee, T; Christie, D; Cohen, M; Suskind, DL; Wahbeh, G; Weber, W, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Spagnuolo, R | 1 |
| Cosco, C | 1 |
| Mancina, RM | 1 |
| Ruggiero, G | 1 |
| Garieri, P | 1 |
| Cosco, V | 1 |
| Doldo, P | 1 |
| Suskind, DL | 1 |
| Wahbeh, G | 1 |
| Burpee, T | 1 |
| Cohen, M | 1 |
| Christie, D | 1 |
| Weber, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Curcumin in Pediatric Inflammatory Bowel Disease: A Forced Dose Titration Study[NCT00889161] | Phase 1 | 11 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Non-Pharmacologic Alternatives for the Treatment of Childhood Obesity in Mexico[NCT03670875] | 300 participants (Actual) | Interventional | 2021-07-31 | Completed | |||
| Phase 2a Randomised Double-blind Placebo-controlled Trial to Assess Safety, Efficacy of Artesunate & Curcumin in Crohn's Disease Patients, Who Continue to Have Mild to Moderate Disease Activity on an Adequate Dose of Azathioprine[NCT04713631] | Phase 2 | 40 participants (Anticipated) | Interventional | 2021-01-21 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for mesalamine and Flatulence
| Article | Year |
|---|---|
Beta-glucan, inositol and digestive enzymes improve quality of life of patients with inflammatory bowel disease and irritable bowel syndrome.
Topics: Abdominal Pain; Anti-Inflammatory Agents, Non-Steroidal; beta-Glucans; Biological Factors; Drug Comb | 2017 |
Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Combined Modality T | 2013 |
Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Combined Modality T | 2013 |
Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Combined Modality T | 2013 |
Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Combined Modality T | 2013 |
Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Combined Modality T | 2013 |
Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Combined Modality T | 2013 |
Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Combined Modality T | 2013 |
Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Combined Modality T | 2013 |
Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Combined Modality T | 2013 |